Jennifer M. Rubatt

Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence

Laura J. Havrilesky, Clark M. Whitehead, Jennifer M. Rubatt et al. · Gynecologic Oncology · 2008 · 231 citations

Biomarker (Medicine), Prognostic Biomarkers, Oncology +12

Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study

Jennifer M. Rubatt, Kathleen M. Darcy, Alan D. Hutson et al. · Gynecologic Oncology · 2009 · 93 citations

P53 Status, Tumoral Pathology, Microvessel Density +7

Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A gynecologic oncology group study

Jennifer M. Rubatt, Kathleen M. Darcy, Chunqiao Tian et al. · Gynecologic Oncology · 2012 · 40 citations · Full text

Pre-treatment Tumor Expression, Medicine, Cancer Management +8

Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines

Brittany A. Davidson, Jennifer M. Rubatt, David L. Corcoran et al. · Frontiers in Oncology · 2014 · 40 citations · Full text

Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells

Deanna Teoh, Tina A. Ayeni, Jennifer M. Rubatt et al. · Gynecologic Oncology · 2011 · 39 citations

Synergistic Activity, Oncology, Medicine +7